

25 November 2021

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

Strategic Alliance for Early Lung Cancer Detection in China

Cizzle Biotechnology, the UK based diagnostics developer, is pleased to announce that it has executed a Memorandum of Understanding ("MOU") with the International Co-Innovation Centre for Advanced Medical Technology ("iCCAMT") and Shenzhen Intelliphecy Life Technologies Co., Ltd. ("Intelliphecy") to develop and market the Company's proprietary early lung cancer diagnostic tests based on the C1Z1B cancer biomarker in China.

Lung cancer is a major public health problem worldwide and especially in China, where it is still the most common diagnosed cancer and the leading cause of cancer related deaths. Early detection is essential in enabling early therapeutic intervention and improved outcomes.

iCCAMT, founded with German Medical Valley, Robert Bosch GmbH and Sinopharm Group, aims to accelerate global med-tech innovation in the Chinese market, by bringing together world leading expertise. The strategic alliance is intended to accelerate product development and clinical trials to achieve early adoption within major cancer centers throughout China.

The MOU is non-binding, but it is intended that a full commercial contract will be entered into in due course whereby the parties will collaborate closely in end-to-end development, manufacture and sale of early cancer detection products and services. The MOU envisages that iCCAMT and Intelliphecy will fund the activities in China and Cizzle Biotechnology will receive payment for monoclonal antibodies and reagents produced, and services provided, together with royalties on any sales of products and services in China.

Initial pilots of Cizzle Biotechnology's lung cancer diagnostic tests are planned at the Cancer Hospital Chinese Academy of Medical Sciences, National Cancer Centre and Beijing Cancer Hospital affiliated with Peking University.

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

"We are delighted to establish this important collaboration to bring our simple blood test for the early detection of lung cancer based on the C1Z1B biomarker to China. In 2020, nearly 715,000 deaths were caused by lung cancer in China, accounting for around 24 percent of all the three million cancer deaths* there. It is a major health and economic challenge and together with our new partners we aim to contribute to building effective strategies for decreasing the cancer burden in China as part of their comprehensive prevention and control measures."

Commenting, Dr Hui Wu, CEO and Founder of iCCAMT said:

"The C1Z1B biomarker developed by Cizzle Biotechnology has shown promising results for lung cancer early detection in the UK. To help the Chinese population access cost-efficient lung cancer detection, the iCCAMT would foster this technology implementation in China with support from its nationwide network of national clinical centers and key opinion leaders."

Commenting, Dr Xiaoyun Huang, CEO and Founder of Intelliphecy said:

"The ability to detect lung cancer at an early stage is key for the improvement of patient survival

and can eventually reduce the medical burden of lung cancer. We are excited to enter into partnership with Cizzle Biotechnology and iCCAMT to develop an early lung cancer diagnostic test based on Cizzle's proprietary technology with the CIZ1B cancer biomarker. We are looking forward to reaching important milestones together with our partners in the near future."

*<https://www.statista.com/statistics/1053667/china-cancer-death-number-by-type/>

This announcement contains inside information for the purposes of article 7 of EU Regulation 596/2014 which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018 ("UK MAR"). Upon the publication of this announcement this inside information is now considered to be within the public domain.

Enquiries:

Cizzle Biotechnology Holdings plc
Allan Syms (Executive Chairman)

Via IFC Advisory

Allenby Capital Limited
John Depasquale
Alex Brearley

+44(0) 20 33285656

Novum Securities Limited
Colin Rowbury
Jon Bellis

+44(0) 20 7399 9400

IFC Advisory Limited
Tim Metcalfe
Florence Chandler

+44(0) 20 3934 6630

Notes to Editors:

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin-out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early stage lung cancer.

For more information, please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

About International Co-Innovation Centre for Advanced Medical Technology ("iCCAMT")

iCCAMT, founded with German Medical Valley, Robert Bosch GmbH, Sinopharm Group, aims to accelerate global healthcare innovation in China. iCCAMT is dedicated to support innovative healthcare SMEs (small and medium sized companies) to grow in China and promote technology

transfer. With global health technology network and supports from industry giants, iCCAMT has developed comprehensive platforms to strengthen cross-border health technology collaborations, and help global health technology companies enter the China market.

For more information, please see <http://www.iccamt.com>

About Shenzhen Intelliphecy Life Technologies Co., Ltd. (“Intelliphecy”)

Intelliphecy is aiming to innovate technologies in the hope to win the war against cancer, aspiring to out-smart cancer cells with an intelligent prophecy. At the core of Intelliphecy’s technology portfolio lies artificial intelligence driven big data analytics, which is devoted to predictive modeling of cancer hallmarks using quantitative information. Its research and development is grounded in both identification of cancer at early stage and prediction of optimal treatment strategies for individual cancer patients. Intelliphecy has established research collaborations with major cancer centres throughout China.

For more information, please see <http://www.intelliphecy.com>